Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional

A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma

ClinicalTrials.gov ID: NCT07941492

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07941492. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are: * What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab? * Is the combination of FHD-286 and mosunetuzumab safe and tolerable? * How many participants have a response to treatment, and how long does the treatment control the disease? * How does treatment affect circulating tumor DNA (ctDNA), immune responses, and molecular markers, including BAF complex mutational status? Researchers will evaluate FHD-286 in combination with mosunetuzumab in participants with relapsed or refractory follicular lymphoma to assess safety, tolerability, and preliminary anti-tumor activity.

Study identification

NCT ID
NCT07941492
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Enrollment
22 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2026 (Estimated)
Primary completion
Dec 2031 (Estimated)
Completion
Dec 2031 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2031

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Weill Cornell Medicine New York New York 10065 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07941492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.